A recent analyst note from HSBC has sent ripples through the market, challenging the prevailing optimism surrounding pharmaceutical giant Eli Lilly. The bank downgraded its rating on the company’s stock to “Reduce” and significantly lowered its price target from $1,070 to $850. This bearish stance stands in stark contrast to the majority of Wall Street analysts and triggered an immediate sell-off, with shares declining nearly six percent following the report’s publication.
Questioning the Obesity Drug Market’s Potential
At the heart of HSBC’s cautious outlook are concerns over the long-term size of the obesity and diabetes drug market. While the current industry consensus forecasts a market exceeding $150 billion, HSBC’s analysis projects a more modest range of $80 to $120 billion by 2032. This substantial forecast gap poses a particular risk to Eli Lilly due to its heavy reliance on this sector.
The company’s fourth-quarter 2025 revenue underscores this concentration. Out of a total $19.29 billion, a commanding $11.67 billion—representing over 60%—was generated by its diabetes and weight-loss medications, Mounjaro and Zepbound. This dependency, according to HSBC, leaves the firm vulnerable to anticipated pricing pressure, which the bank forecasts could emerge as soon as 2026.
Pipeline Uncertainty and Competitive Pressures
Further skepticism from HSBC centers on Eli Lilly’s developmental oral weight-loss drug, Orforglipron. Awaiting FDA approval with a potential launch in April or early summer 2026, the drug’s commercial prospects are viewed with caution. The analyst warns that consensus sales estimates may be overly optimistic, potentially driven by assumptions of inventory buildup rather than genuine end-user demand. Clinical data also reveals that a significant portion of patients discontinue GLP-1 therapies over the long term, adding another layer of uncertainty.
Should investors sell immediately? Or is it worth buying Eli Lilly?
This outlook presents a clear divergence from Eli Lilly’s own guidance. The company has provided revenue projections for the full year 2026 between $80 and $83 billion, with earnings per share estimated in the range of $33.50 to $35.00. Furthermore, a notable contrast exists with its main competitor, Novo Nordisk, which has issued markedly more conservative sales estimates.
A Sector Under Scrutiny
Despite HSBC’s warning, the broader analyst community remains largely bullish. The average price target for Eli Lilly shares sits well above $1,200, with most firms maintaining “Buy” or equivalent recommendations. However, a key vulnerability highlighted for both Eli Lilly and Novo Nordisk is their significant exposure to the “cash-pay” channel—patients paying out-of-pocket without insurance coverage. This makes their revenues more susceptible to broader economic conditions.
The coming year is set to be a critical test for the entire GLP-1 sector. The extent to which potential price declines in 2026 will impact profit margins will likely force a comprehensive reevaluation of these high-flying stocks. For now, HSBC’s report serves as a pointed reminder of the risks embedded in Eli Lilly’s current valuation.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from March 20 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 20.
Eli Lilly: Buy or sell? Read more here...
